Journal article
Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non–ST-Segment Elevation Acute Coronary Syndromes
Abstract
BACKGROUND: The Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) trials evaluated fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST- and ST-segment elevation acute coronary syndromes, respectively. Combined results for these 2 trials on major efficacy and safety outcomes and data on the effects of fondaparinux in relation to interventional management strategy have not been previously …
Authors
Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P
Journal
Circulation, Vol. 118, No. 20, pp. 2038–2046
Publisher
Wolters Kluwer
Publication Date
November 11, 2008
DOI
10.1161/circulationaha.108.789479
ISSN
0009-7322